Daily Disruptor: $AEHR, the AI chip stress test with $100M already booked

The 30 second version

• Aehr Test Systems builds machines that stress AI chips hot and hard before they ship, so weak ones die in the factory and not in a data centre.
• Its AI burn in business is at Liftoff: the binding constraint is screening ever hotter, ever pricier chip packages at production speed, and two AI customers have now cleared it.
• The evidence: an effective backlog of $100.6M in July, double last year’s revenue, then $28M more in announced AI orders, including one for a customer’s second chip generation.
• Next test: first quarter results on November 2, where guidance of $130M to $150M for the year to June 2027 has to hold.
• It breaks if that guidance falls below $130M, if backlog drops under $75M, or if the hyperscaler’s second chip slips out of calendar 2027.

Two years ago, more than 95% of Aehr Test Systems’ revenue came from silicon carbide chips for electric cars. In the fiscal year that ended in May, that business was under 5% of sales, and the company still finished the year holding $100.6M of orders, twice everything it sold in those twelve months.

The shares have gone the other way. They sit near $69 going into Friday, roughly half their 52 week high, after a drop of about a third since early October that we could not tie to anything the company has filed or said. In the middle of that slide, its largest package level customer ordered more machines for a chip that is not yet in production.

On November 2, seventeen days from now, Aehr reports the first quarter of its new fiscal year. It is the first hard look at whether that backlog is shipping on schedule.

What just happened

On October 7, Aehr announced about $6M of follow on orders from its lead hyperscale customer for Sonoma, its package level burn in system. The order covers more systems, turnkey burn in modules, device specific sockets and software, all going to the customer’s assembly and test contractor in Taiwan over the next six months. The chip is the customer’s second AI processor on Sonoma, and the customer has told Aehr it expects this one to reach higher volumes than the first, which is already in high volume production.

Six million dollars is small next to the record $41M order from the same customer in April. What matters is that a buyer who qualified Sonoma for one chip has picked it again for the next, harder one, which needs separately controlled thermal zones inside each package. Aehr says talks on later generations now cover both Sonoma and its FOX wafer level platform.

The other AI customer moved first. On August 12, Aehr’s lead wafer level AI processor customer placed a $22M follow on order for several FOX XP systems, each of which burns in nine 300mm wafers at once, with shipments over six months to the customer’s manufacturing partner in Taiwan. Aehr said that customer’s production plans already assume capacity beyond this order.

The business

Burn in is the step where chips are run hot, at raised voltage, for hours, so that parts carrying hidden defects fail early. Aehr does it in two places. FOX systems do it on the whole wafer, before the chips are cut apart and packaged. Sonoma, which came with the Incal Technology acquisition, does it on the finished package.

The money comes in two layers. First the system: on the fourth quarter call, chief executive Gayn Erickson put production Sonoma units, consumables included, at roughly $600,000 to $700,000 apiece. Then the consumables, which are specific to each chip design: WaferPak full wafer contactors for FOX, burn in modules and sockets for Sonoma. Contactor revenue was $5.8M in the May quarter, 31% of the total, and it resets with every new device a customer brings onto the platform.

The customer’s arithmetic is simple. An AI accelerator package puts a costly compute die next to stacks of high bandwidth memory, so a die that fails after packaging takes everything around it into the scrap bin. Screen the die on the wafer and the loss is one die. That is why Aehr’s lead wafer level AI customer, per the July results release, is moving all of its accelerator burn in from system level to wafer level.

One detail from the July filing: the fourth quarter’s GAAP profit of $1.4M came from the tax line. Aehr lost $1.2M from operations and booked a $1.8M income tax benefit. Package level burn in is a field with established rivals, and customers can always fall back on testing whole boards. Wafer level burn in at these power levels is where Aehr argues it has almost nobody beside it, and the repeat orders are the best support for that claim.

Where it sits on our curve

Our Disruption Map puts semiconductor test and burn in at Liftoff. The AI build out created a reliability step that did not exist at this scale, and its suppliers are being chosen now, chip program by chip program. Aehr’s AI burn in business sits there too. The binding constraint is power and value per package: the hyperscaler’s second chip draws twice the power per package of the first, and the buyer only acts when a tool can screen that at production speed in a contractor’s factory, for less than the packages it saves.

Both AI customers have crossed that threshold, and both have gone past a first purchase to a second round. On our evidence sequence that is expansion: paid production systems, then repeat orders, then a second chip generation on the same platform. Silicon photonics shows the same pattern, with a follow on order from the lead customer in July and a second, unrelated networking company forecasting more systems this calendar year. Cash is close behind: operating cash use was only $3.3M in fiscal 2026 while backlog built.

For the curve to steepen, a third AI chip company has to pay. In July, Aehr said a top tier supplier of AI accelerators, CPUs and network processors finished a wafer level benchmark with results above its expectations, wants to move to pilot production validation, and has asked Aehr to evaluate a second device. The strongest alternative reading is plain: this is a capacity burst from two customers that will be followed by a digestion year, as test equipment so often is. Consumable orders for new designs and a paid pilot from that third company are what separate the two stories.

The numbers

The turn shows in the quarters. Revenue was $14.1M in the May 2025 quarter, about $20.9M across the two quarters that followed combined, $10.3M in the February quarter, then $18.8M in the May 2026 quarter. Fiscal 2026 revenue fell to $50.0M from $59.0M as silicon carbide collapsed. Backlog went the other way, from $15.2M to $80.6M, with record quarterly bookings of $60.7M.

Margins are moving with volume. Adjusted gross margin was 45% in the fourth quarter against 35% a year earlier, on mix and better factory use. Guidance for the year ending June 25, 2027 is revenue of $130M to $150M, with adjusted net income at 18% to 22% of revenue. Aehr changed its year end from May to June, so the four weeks to June 26 sit in a transition period outside fiscal 2027.

The cadence will be lumpy, and November 2 should be read with that in mind. On the July call, management said the first quarter should be “pretty good”, the second “very strong”, with the bulk of the $41M April order shipping then, the third roughly flat and the fourth higher. A soft looking first quarter on its own is not the signal; guidance and backlog are.

The balance sheet is clean. Cash was $116.5M at May 29 with no borrowings, after $97.4M of net proceeds from share sales during the year. That raise cost holders: diluted shares in the May quarter were 33.2M against 29.8M a year earlier, up about 11%. Street estimates we could see sit near the guidance midpoint, though we could not confirm them against a primary source.

What the price already requires

At about $69 and 33M diluted shares, Aehr is worth about $2.3B, or $2.2B net of cash. At the guidance midpoint and a 20% net margin, that is around 80 times this year’s adjusted earnings. Put a steady 30 times multiple on it instead and the price needs about $75M of net income, which at a 23% to 24% margin means roughly $320M of revenue by fiscal 2029, about 50% growth a year after this one.

Our downside: AI adoption stops at today’s two customers, capacity gets digested, and fiscal 2029 revenue is about $170M at a 20% margin. That is worth roughly $1.1B, half today’s price. Our central case: $140M this year, about $210M next, and about $320M in fiscal 2029 as the hyperscaler’s second chip and photonics ramp, with consumables rising alongside the installed base. That supports today’s price with little to spare. Upside: the third AI chip company moves into production and fiscal 2029 reaches $450M or more, worth about $3.5B.

So where is the gap? Guidance covers the current backlog and existing production programs. It does not include the top tier supplier now asking for a pilot, and it captures only the start of a second hyperscaler chip the customer expects to outsell the first. The market prices Aehr as a supplier riding two customers’ capital budgets. We read customers coming back for their next chip, and a consumables bill that resets each time they do.

What breaks it

Written now, before the test: guidance cut below $130M on November 2, or backlog at the end of the September quarter below $75M, breaks the thesis. Either means shipments are not being replaced: the digestion story. A slip of the hyperscaler’s second chip ramp beyond calendar 2027 breaks it too, because our central case leans on it.

The next most likely failure is concentration. Two AI customers likely carry most of the backlog, though Aehr does not break it out, and one quiet quarter from either moves the whole number. Financing is not the issue: Aehr reaches the test, and the cash from the backlog, on what it holds, and we expect it to stay self funding. A fresh share sale without a clear need would count against the thesis anyway, because value per share is what we own.

What we are watching

• November 2, 2026, first quarter results: strengthens if fiscal 2027 guidance is held or raised, backlog is $95M or more, and a pilot order from the third AI chip company is disclosed. Breaks if guidance drops below $130M or backlog falls under $75M.
• December 2026: the networking photonics customer’s forecast systems for this calendar year. Booked orders strengthen the case for a third end market; no order by the February report weakens it.
• Early February 2027, second quarter results (date not yet set): the bulk of the $41M Sonoma order ships. Revenue of $40M or more strengthens; under $30M without a matching new order breaks the cadence management described.
• April 2027 and through calendar 2027: October’s Sonoma deliveries complete, then the hyperscaler’s second chip ramps. Larger follow on orders for that chip strengthen; a ramp pushed into 2028 breaks the thesis.

Not financial advice.

References

1. Aehr Test Systems. Form 8-K, Exhibit 99.1: Aehr Test Systems Reports Fiscal 2026 Fourth Quarter and Full Year Financial Results with Record Quarterly Bookings and $100 Million Effective Backlog. US Securities and Exchange Commission. Published July 14, 2026. Accessed October 15, 2026. https://www.sec.gov/Archives/edgar/data/1040470/000165495426006655/aehr_ex991.htm
2. The Motley Fool. Aehr Test Systems (AEHR) Q4 2026 Earnings Call Transcript, as republished. The Globe and Mail. Published July 15, 2026. Accessed October 15, 2026. https://www.theglobeandmail.com/investing/markets/markets-news/motley/3286028/aehr-test-systems-aehr-q4-2026-earnings-call-transcript/
3. Aehr Test Systems. Aehr Receives Follow On Sonoma Production Orders for Lead Hyperscale Customer’s Next Generation AI Processor. Published October 7, 2026. Accessed October 15, 2026. https://www.aehr.com/2026/10/aehr-receives-follow-on-sonoma-production-orders-for-lead-hyperscale-customer-s-next-generation-ai-processor/
4. Aehr Test Systems. Aehr Test Systems to Announce First Quarter Fiscal 2027 Financial Results on November 2, 2026. Published October 8, 2026. Accessed October 15, 2026. https://www.aehr.com/2026/10/aehr-test-systems-to-announce-first-quarter-fiscal-2027-financial-results-on-november-2-2026/
5. US Tech. Aehr Receives Record $41 Million Production Order (company release). Published April 2026. Accessed October 15, 2026. https://www.us-tech.com/RelId/2784406/registered/1/ISvars/showpage/Aehr_Receives_Record_41_Million_Production_Order.htm
6. Investing.com. Aehr Test Systems receives record $41 million AI chip order. Investing.com. Published April 16, 2026. Accessed October 15, 2026. https://www.investing.com/news/company-news/aehr-test-systems-receives-record-41-million-ai-chip-order-93CH-4617855
7. Investing.com. Aehr Test Systems receives $22 million AI processor order. Investing.com. Published August 12, 2026. Accessed October 15, 2026. https://www.investing.com/news/company-news/aehr-test-systems-receives-22-million-ai-processor-order-93CH-4854596
8. StreetInsider. Aehr Test Systems receives $22M follow on order for AI burn in systems. StreetInsider. Published August 12, 2026. Accessed October 15, 2026. https://www.streetinsider.com/Corporate+News/Aehr+Test+Systems+receives+$22M+follow-on+order+for+AI+burn-in+systems/26908942.html
9. The Motley Fool. Aehr Test Systems (AEHR) Q4 2026 Earnings Call Transcript. The Motley Fool. Published July 14, 2026. Accessed October 15, 2026. https://www.fool.com/earnings/call-transcripts/2026/07/14/aehr-test-systems-aehr-q4-2026-earnings-call-transcript/
10. Investing.com. Aehr Test Systems receives silicon photonics production order. Investing.com. Published July 9, 2026. Accessed October 15, 2026. https://www.investing.com/news/company-news/aehr-test-systems-receives-silicon-photonics-production-order-93CH-4783806
11. Investing.com. Earnings call transcript: Aehr Test Systems tops Q4 2026 forecasts, stock jumps 29%. Investing.com. Published July 14, 2026. Accessed October 15, 2026. https://www.investing.com/news/transcripts/earnings-call-transcript-aehr-test-systems-tops-q4-2026-forecasts-stock-jumps-29-93CH-4791974